Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 19/20 | 0.42 |
| ▸ | MC5R | P33032 | 18/20 | 0.42 |
| ▸ | MC3R | P41968 | 9/20 | 0.42 |
| ▸ | MC1R | Q01726 | 8/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9250611 | 0.87 | MC4R (0.39) | MC4RMC5RMC3RMC1R | |
| SCHEMBL14040514 | 0.85 | MC4R (0.35) | MC4RMC5RMC3RMC1R | |
| SCHEMBL6528107 | 0.84 | MC4R (0.51) | MC4RMC5RMC3RMC1REPHX1 | |
| SCHEMBL14040642 | 0.84 | CNR2 (0.37) | MC4RMC5RMC3RMC1REPHX1 | |
| SCHEMBL1309006 | 0.82 | EPHX1 (0.41) | EPHX1 | |
| SCHEMBL13677292 | 0.80 | MC4R (0.46) | MC4RMC5RMC3RMC1R | |
| SCHEMBL14111012 | 0.79 | MC4R (0.45) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13270912 | 0.77 | MC4R (0.37) | MC4RMC5RMC3RMC1R | |
| SCHEMBL13676985 | 0.77 | MC4R (0.44) | MC4RMC5RMC3RMC1R | |
| Iodide SCHEMBL3144450 | 0.76 | MC4R (0.37) | MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150329522-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-11-19 | — | — | US | disclosed |
| US-8962846-B2 | Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| EP-2352729-B1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-14 | — | — | EP | disclosed |
| WO-2012131090-A1 | METHOD FOR TREATMENT OF XERODERMA PIGMENTOSUM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-04 | — | — | WO | disclosed |
| US-20110281913-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-17 | — | — | US | disclosed |
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| EP-2068867-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7414057-B2 | Piperazine urea derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-10-26 | — | — | US | disclosed |
| EP-1603912-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| EP-1603911-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005047253-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
| EP-1468999-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MyoContract Ltd. (CH) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004083208-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083209-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| EP-1460073-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MyoContract Ltd. (CH) | 2004-09-22 | — | — | EP | disclosed |
| US-6458790-B2 | DIETETICS; ANTIDABETIC AGENTS; SEXUAL DISRDERS | MERCK & CO., INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020019523-A1 | Substituted piperidines as melanocortin receptor agonists | MERCK SHARP & DOHME CORP. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | MC4R 1/4885MC5R 2/4885MC3R 3/4885 |
| US-20150329522-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | MC1R, MC5R, MC3R | MC4R 4/4885MC5R 2/4885MC3R 3/4885 |
| US-20110281913-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | MC1R, MC5R, MC3R | MC4R 4/4885MC5R 2/4885MC3R 3/4885 |
| US-20020019523-A1 | Substituted piperidines as melanocortin receptor agonists | MC4R, MC5R, MC3R | MC4R 1/4885MC5R 2/4885MC3R 3/4885 |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | MC4R 1/4885MC5R 2/4885MC3R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.